Suppr超能文献

[针对刺突蛋白的抗严重急性呼吸综合征冠状病毒2药物的研究进展]

[Research Progress in the Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drugs Targeting Spike Protein].

作者信息

Geng Jia-Yi, Sun Hao, Ni Qiang, Li Qiu-Yu

机构信息

Department of Respiratory and Critical Care Medicine,Peking University Third Hospital,Beijing 100191,China.

出版信息

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Dec;44(6):1056-1062. doi: 10.3881/j.issn.1000-503X.15002.

Abstract

The coronavirus disease 2019(COVID-19) caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is spreading around the world,while the specific drugs targeting SARS-CoV-2 are still under development.On the basis of the biological characteristics of SARS-CoV-2 and the key protein(spike protein) for viral replication,this paper introduces the research progress in the action sites of related drugs,providing information for clinical application and ideas for development of anti-SARS-CoV-2 drugs.

摘要

由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)正在全球蔓延,而针对SARS-CoV-2的特效药物仍在研发中。基于SARS-CoV-2的生物学特性及病毒复制关键蛋白(刺突蛋白),本文介绍了相关药物作用位点的研究进展,为临床应用提供信息,并为抗SARS-CoV-2药物的研发提供思路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验